Estradiol undecylate/norethisterone enanthate

{{Short description|Combination drug}}

{{Drugbox

| image = Estradiol undecylate.svg

| width = 250px

| caption =

| image2 = Norethindrone enanthate.svg

| width2 = 250px

| caption2 = Estradiol undecylate (top) and
norethisterone enanthate (bottom)

| type = combo

| drug_name = Estradiol undecylate /
norethisterone enanthate

| component1 = Estradiol undecylate

| class1 = Estrogen

| component2 = Norethisterone enanthate

| class2 = Progestogen

| tradename =

| Drugs.com =

| MedlinePlus =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category =

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status =

| routes_of_administration = Intramuscular injection

| CAS_number =

| ATC_prefix =

| ATC_suffix =

| PubChem =

| DrugBank =

| synonyms = EU/NETE

}}

Estradiol undecylate/norethisterone enanthate (EU/NETE) is a combination medication of estradiol undecylate (EU), an estrogen, and norethisterone enanthate (NETE), a progestin, which was developed by Schering for potential use as a combined injectable contraceptive in women but was ultimately never marketed.{{cite journal | vauthors = Karim M, el-Mahgoub S | title = Conception control by cyclic injections of norethisterone enanthate and estradiol unducelate | journal = Am. J. Obstet. Gynecol. | volume = 110 | issue = 5 | pages = 740–2 | date = July 1971 | pmid = 5563241 | doi = 10.1016/0002-9378(71)90268-7 }}{{cite journal | vauthors = Toppozada MK | title = Existing once-a-month combined injectable contraceptives | journal = Contraception | volume = 49 | issue = 4 | pages = 293–301 | year = 1994 | pmid = 8013216 | doi = 10.1016/0010-7824(94)90029-9 }}{{cite book | author = Mokhtar K. Toppozada | chapter = Monthly Injectable Contraceptives | pages = 93–103 | editor1 = Alfredo Goldsmith | editor2 = Mokhtar Toppozada | title = Long-Acting Contraception | year = 1983 | oclc = 35018604 | url = https://scholar.google.com/scholar?cluster=14664537528797672080}}{{cite journal | vauthors = Toppozada M | title = The clinical use of monthly injectable contraceptive preparations | journal = Obstet Gynecol Surv | volume = 32 | issue = 6 | pages = 335–47 | date = June 1977 | pmid = 865726 | doi = 10.1097/00006254-197706000-00001 }}{{cite book|author=Dr. S. S. Kadam|title=Principles of Medicinal Chemistry Volume 2|url=https://books.google.com/books?id=Z7Pb3lJuRksC&pg=PA381|date=July 2007|publisher=Pragati Books Pvt. Ltd.|isbn=978-81-85790-03-9|pages=381–}}{{cite journal | vauthors = Newton JR, D'arcangues C, Hall PE | title = A review of "once-a-month" combined injectable contraceptives | journal = J Obstet Gynaecol (Lahore) | volume = 4 | pages = S1–34 | year = 1994 | issue = Suppl 1 | pmid = 12290848 | doi = 10.3109/01443619409027641}} It contained 5 to 10 mg EU and 50 to 70 mg NETE in oil solution and was intended for use by intramuscular injection at regular intervals. Although never commercialized, EU/NETE was found to be effective and well tolerated.